Organon & Co. (OGN)

99 Views25 Jul 2026 11:00

Syndicated

SUMMARY

With the stockholder vote passed and Sun Pharma’s financing syndicated, the equity is no longer a claim on a pharmaceutical business but on a $14.00 cash payment; the question is whether a 3.9% spread pays for a 44% tail.
Organon trades as a merger stub against Sun Pharma’s $14.00 all-cash offer.
The decisive fact is that the heavy conditions are behind it: stockholders approved the deal on 23 July, the HSR notification was filed on 21 May, and the acquisition financing has been fully syndicated.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream